Research on the Value of G3BP1 Protein as a Biomarker in the Early Diagnosis of Gastric Cancer
Research Article
Open Access
CC BY

Research on the Value of G3BP1 Protein as a Biomarker in the Early Diagnosis of Gastric Cancer

Wanyue Zeng 1*
1 Guangdong Experiment High School, Guangzhou, 510375, China
*Corresponding author: wanyue_z_2026@163.com
Published on 24 September 2025
Journal Cover
TNS Vol.137
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-80590-371-0
ISBN (Online): 978-1-80590-372-7
Download Cover

Abstract

Gastric cancer is one of the major issues for world health. Although patients have a poor five-year survival rate, early detection can significantly improve the prognosis. There are some issues with today’s diagnostic techniques, such as positron emission tomography-computerized tomography (PET-CT) and endoscopic ultrasound (EUS). In this work, we investigate the G3BP1 protein as a potential biomarker for the early detection of gastric cancer. We use tumors from MKN1 xenograft mice and adjacent healthy tissues. We predicted that in cancer cells, HSU mRNA levels would decrease and G3BP1 would rise. In the experiments, we used the gastric cancer cell lines MGC-803 and AGS and the human stomach epithelial cell line GES-1. We created detecting systems like the luciferase and GFP systems. Confocal microscopy, Western blot analysis, cell transfection, and reverse transcription-polymerase chain reaction (RT-PCR) were among the experimental techniques used. There were eight combinations for the outcomes. The theory was completely supported by CR1. It showed how gastric cancer development may be influenced by both the increase in G3BP1 and the decrease in HSU mRNA. However, CR8 was entirely opposed to the notion, whereas CR2–CR7 only partially supported it. These findings indicate that there is a complicated interaction between G3BP1 and HSU mRNA in the gastric cancer development. In order to understand these interactions and clarify biomarkers for early diagnosis, we will adopt gene editing methods and multi-omics analysis in the future.

Keywords:

G3BP1, Biomarker, Gastric Cancer, Early Diagnosis

View PDF
Zeng,W. (2025). Research on the Value of G3BP1 Protein as a Biomarker in the Early Diagnosis of Gastric Cancer. Theoretical and Natural Science,137,18-26.

References

[1]. International Agency for Research on Cancer. GLOBAL CANCER. World Health Organization. GLOBOCAN 2022. Retrieved from https: //gco.iarc.who.int/media/globocan/factsheets/cancers/7 - stomach - fact sheet.pdf

[2]. Endoscopic ultrasound, Mayo Clinic. (2022). Retrieved from https: //www.mayoclinic.org/tests-procedures/endoscopic-ultrasound/about/pac-20385171

[3]. Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging. Insights Imaging. 2011; 2(6): 679 - 698. doi: 10.1007/s13244 - 010 - 0062 - 3

[4]. Ge Y, Jin J, Li J, Ye M, Jin X. The roles of G3BP1 in human diseases (review). Gene. 2022; 821: 146294. DOI: 10.1016/j.gene.2022.146294

[5]. Fischer JW, Busa VF, Shao Y, Leung AKL. Structure: Mediated RNA Decay by UPF1 and G3BP1. Mol Cell. 2020; 78(1): 70-84. e6. DOI: 10.1016/j.molcel.2020.01.021

[6]. Xiong R, Gao JL, Yin T. G3BP1 activates the TGF-β/Smad signaling pathway to promote gastric cancer. Onco Targets Ther. 2019; 12: 7149-7156. Published 2019 Sep 2. doi: 10.2147/OTT.S213728

Cite this article

Zeng,W. (2025). Research on the Value of G3BP1 Protein as a Biomarker in the Early Diagnosis of Gastric Cancer. Theoretical and Natural Science,137,18-26.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-371-0(Print) / 978-1-80590-372-7(Online)
Editor: Alan Wang
Conference date: 17 October 2025
Series: Theoretical and Natural Science
Volume number: Vol.137
ISSN: 2753-8818(Print) / 2753-8826(Online)